Published in N Engl J Med on January 27, 1983
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol (2011) 2.55
Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med (1994) 2.45
The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy. Inflammopharmacology (2010) 2.05
Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. Neuroimage (2010) 1.71
Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology (2009) 1.62
"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (1998) 1.56
A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry (2005) 1.50
Multiple sclerosis-a quiet revolution. Nat Rev Neurol (2015) 1.47
Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One (2013) 1.45
Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest (1998) 1.36
Central motor conduction in multiple sclerosis: evaluation of abnormalities revealed by transcutaneous magnetic stimulation of the brain. J Neurol Neurosurg Psychiatry (1988) 1.31
EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry (1992) 1.29
Long-term efficacy of miglustat in paediatric patients with Niemann-Pick disease type C. J Inherit Metab Dis (2012) 1.15
Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry (1999) 1.14
Quantitative measures detect sensory and motor impairments in multiple sclerosis. J Neurol Sci (2011) 1.14
Autoimmune optic neuropathy: evaluation and treatment. J Neurol Neurosurg Psychiatry (1988) 1.10
Standards for the use of ordinal scales in clinical trials. Br Med J (Clin Res Ed) (1986) 1.08
Prospects for the treatment of multiple sclerosis. J R Soc Med (1991) 1.07
Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol (2014) 1.04
Changes in locomotor muscle activity after treadmill training in subjects with incomplete spinal cord injury. J Neurophysiol (2008) 1.04
The Charcot Lecture | beating MS: a story of B cells, with twists and turns. Mult Scler (2014) 1.02
Preferential expression of mutant ABCD1 allele is common in adrenoleukodystrophy female carriers but unrelated to clinical symptoms. Orphanet J Rare Dis (2012) 0.93
Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. J Neurol Neurosurg Psychiatry (2002) 0.92
Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system. A report of six cases. J Neurol (2004) 0.92
Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol (2015) 0.92
Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry (1989) 0.90
Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis. West J Med (1994) 0.89
Functional magnetic resonance imaging movers and shakers: does subject-movement cause sampling bias? Hum Brain Mapp (2012) 0.88
More immunotherapy for multiple sclerosis. J Neurol Neurosurg Psychiatry (1996) 0.88
Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost? J Neurol Neurosurg Psychiatry (2001) 0.87
Natalizumab in the treatment of multiple sclerosis. Ther Clin Risk Manag (2009) 0.86
Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Ther Adv Neurol Disord (2009) 0.85
Muscle synergies and spinal maps are sensitive to the asymmetry induced by a unilateral stroke. J Neuroeng Rehabil (2015) 0.85
Prevalence and burden of gait disorders in elderly men and women aged 60-97 years: a population-based study. PLoS One (2013) 0.85
Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry (1991) 0.85
Chemotherapeutics in the treatment of multiple sclerosis. Ther Adv Neurol Disord (2010) 0.85
Harnessing the integrated stress response for the treatment of multiple sclerosis. Lancet Neurol (2016) 0.84
Pediatric multiple sclerosis. NeuroRx (2006) 0.84
Mycobacteria infection in incomplete transverse myelitis is refractory to steroids: a pilot study. Clin Dev Immunol (2011) 0.83
Mitoxantrone in worsening secondary progressive multiple sclerosis: A prospective, open-label study. Curr Ther Res Clin Exp (2006) 0.83
Microstructural changes in the striatum and their impact on motor and neuropsychological performance in patients with multiple sclerosis. PLoS One (2014) 0.83
Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. J Neurol (2004) 0.83
Self-efficacy as a predictor of self-reported physical, cognitive, and social functioning in multiple sclerosis. Rehabil Psychol (2013) 0.83
Validity and Reliability of the Greek Version of the Multiple Sclerosis International Quality-of-Life Questionnaire. J Clin Neurol (2009) 0.82
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. Autoimmune Dis (2011) 0.81
Role of immunosuppressive therapy for the treatment of multiple sclerosis. Neurotherapeutics (2013) 0.81
Costeff syndrome: clinical features and natural history. J Neurol (2014) 0.81
Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves. J Neurol Neurosurg Psychiatry (1999) 0.81
Capacity to make medical treatment decisions in multiple sclerosis: a potentially remediable deficit. J Clin Exp Neuropsychol (2010) 0.81
The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial. ISRN Neurol (2013) 0.80
Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study. J Neurol (2006) 0.80
Immunotherapy for multiple sclerosis. J Neurol Neurosurg Psychiatry (1994) 0.80
Effect of cyclic, low dose pyrimethamine treatment in patients with Late Onset Tay Sachs: an open label, extended pilot study. Orphanet J Rare Dis (2015) 0.79
Risk factors in multiple sclerosis: a population-based case-control study in Sicily. Background and methods. Neurol Sci (2016) 0.79
Plasma exchange in neurological diseases. Br Med J (Clin Res Ed) (1987) 0.79
Validation of the spanish version of the Multiple Sclerosis International Quality of Life (Musiqol) questionnaire. BMC Neurol (2011) 0.79
Memory impairment in multiple sclerosis is due to a core deficit in initial learning. J Neurol (2013) 0.78
A placebo-controlled trial of isoprinosine in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (1994) 0.78
Total lymphoid irradiation in multiple sclerosis. J Neurol Neurosurg Psychiatry (1994) 0.78
Access and barriers to MS care in Latin America. Mult Scler J Exp Transl Clin (2017) 0.77
Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. The Ginkgolide Study Group in multiple sclerosis. J Neurol Neurosurg Psychiatry (1995) 0.77
Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease. Ther Adv Neurol Disord (2016) 0.77
Disease-modifying therapy of pediatric multiple sclerosis. Neurotherapeutics (2013) 0.77
How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms. J Interferon Cytokine Res (2014) 0.77
Efficacy of cyclophosphamide in sarcoid radiculomyelitis. J Neurol Neurosurg Psychiatry (1992) 0.77
A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data. J Neurol (1996) 0.76
Diagnosis and Management of Multiple Sclerosis in Children. Iran J Child Neurol (2016) 0.75
Where now for therapeutic apheresis? Br Med J (Clin Res Ed) (1984) 0.75
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. PLoS One (2017) 0.75
Infusion of autologous adipose tissue derived neuronal differentiated mesenchymal stem cells and hematopoietic stem cells in post-traumatic paraplegia offers a viable therapeutic approach. Adv Biomed Res (2016) 0.75
Paradoxical effects of temperature in multiple sclerosis. J Neurol Neurosurg Psychiatry (1987) 0.75
Managing advanced multiple sclerosis. Can Fam Physician (1993) 0.75
Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. Autoimmunity (1994) 0.75
Cytotoxic drugs for non-neoplastic disease. Br Med J (Clin Res Ed) (1983) 0.75
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler (2017) 0.75
Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study. J Res Med Sci (2012) 0.75
Double-blind controlled trial of azathioprine in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry (1987) 0.75
Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study. BMC Neurol (2017) 0.75
Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science (1994) 8.69
B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell (1995) 6.88
Climate change and evolution: disentangling environmental and genetic responses. Mol Ecol (2008) 5.34
Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A (1992) 4.94
Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet (1996) 4.77
T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature (1990) 4.40
Molecular basis of reovirus virulence: role of the S1 gene. Proc Natl Acad Sci U S A (1977) 3.97
Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol (2001) 3.86
The immunologic significance of antigen induced lymphocyte transformation in vitro. J Immunol (1966) 3.79
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology (2008) 3.68
Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med (1999) 3.66
Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet (1992) 3.53
Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature (1995) 3.46
Effects of oral administration of type II collagen on rheumatoid arthritis. Science (1993) 3.32
Absolute linkage of virulence and central nervous system cell tropism of reoviruses to viral hemagglutinin. J Infect Dis (1980) 3.27
The effect of kaolin on immunoglobulins: an improved technique to remove the nonspecific serum inhibitor of reovirus hemagglutination. J Immunol (1967) 3.17
Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med (2000) 3.15
Hazard of overwhelming infection after splenectomy in childhood. N Engl J Med (1967) 3.14
CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A (1999) 3.07
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet (1996) 2.98
A simple method for DNA purification from peripheral blood. Anal Biochem (1988) 2.98
Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science (1993) 2.97
IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J Immunol (1998) 2.93
Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science (1990) 2.86
Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci U S A (1994) 2.82
Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A (1991) 2.72
Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol (1997) 2.64
Antigen-driven bystander suppression after oral administration of antigens. J Exp Med (1991) 2.62
Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol (1988) 2.59
Seasonal prevalence of MS disease activity. Neurology (2010) 2.59
Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol (1993) 2.56
Oxidative damage in Alzheimer's. Nature (1996) 2.55
The comparative enzymology of creatine kinases. I. Isolation and characterization from chicken and rabbit tissues. J Biol Chem (1967) 2.54
Neutralization of reovirus: the gene responsible for the neutralization antigen. J Exp Med (1977) 2.53
Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology (2004) 2.50
Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med (1994) 2.45
Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol (1994) 2.43
Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology (1995) 2.42
Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics (1993) 2.39
Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler (1999) 2.35
Continuous subcutaenous administration of deferoxamine in patients with iron overload. N Engl J Med (1977) 2.31
Late complications of immune deviation therapy in a nonhuman primate. Science (1996) 2.30
HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology (2010) 2.29
Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature (1986) 2.29
Identification of the gene coding for the hemagglutinin of reovirus. Virology (1978) 2.28
Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest (1996) 2.27
In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med (1985) 2.27
Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies. N Engl J Med (1980) 2.21
Demyelinative myelopathy in mice induced by the DA virus. J Neurol Sci (1976) 2.20
Selective sparing of a class of striatal neurons in Huntington's disease. Science (1985) 2.16
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med (1996) 2.14
Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J Immunol (1990) 2.13
Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J Immunol (1990) 2.09
Alterations in immunoregulatory T cell subsets in active systemic lupus erythematosus. J Clin Invest (1980) 2.06
Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci U S A (1996) 2.06
Surgery for angiographically occult cerebral aneurysms. J Neurosurg (1993) 2.06
Interaction of reovirus with cell surface receptors. I. Murine and human lymphocytes have a receptor for the hemagglutinin of reovirus type 3. J Immunol (1980) 2.06
Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem (1993) 2.06
Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol (1986) 2.06
Oxidative stress in patients with Friedreich ataxia. Neurology (2000) 2.03
Age-dependent increases in oxidative damage to DNA, lipids, and proteins in human skeletal muscle. Free Radic Biol Med (1999) 2.03
HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet (2003) 2.02
T-cell recognition of myelin basic protein. Immunol Today (1991) 1.98
Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci (2001) 1.95
Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A (1997) 1.95
An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci U S A (1991) 1.93
A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol (1987) 1.92
Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol (1999) 1.91
Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem (1997) 1.90
Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology (1993) 1.88
Common T-cell receptor V beta usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis. Ann Neurol (1991) 1.85
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology (1993) 1.81
Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1997) 1.80
Oxidative stress in Huntington's disease. Brain Pathol (1999) 1.80
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci (2000) 1.79
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med (1999) 1.79
Patterns of cytomegaloviral complement-fixing antibody activity: a longitudinal study of blood donors. J Infect Dis (1973) 1.78
T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol (1995) 1.78
Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol (2001) 1.77
Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol (1999) 1.77
Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain. J Thromb Haemost (2006) 1.75
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology (2009) 1.73
Monoclonal antibody identification of a 100-kDa membrane protein in HeLa cells and human spinal cord involved in poliovirus attachment. Proc Natl Acad Sci U S A (1988) 1.73
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology (2006) 1.73
Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol (1997) 1.71
Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem (1994) 1.69
Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A (1998) 1.68
Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am J Hum Genet (1995) 1.67
Antigen microarrays identify CNS-produced autoantibodies in RRMS. Neurology (2012) 1.67
Oral tolerance: mechanisms and therapeutic applications. Adv Immunol (1999) 1.65
Identification of a hemagglutinin-specific idiotype associated with reovirus recognition shared by lymphoid and neural cells. J Exp Med (1982) 1.64
Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J Neurosci (2001) 1.64
Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum Mol Genet (1998) 1.63